| Expression | AKAP12 isoforms are expressed in most tissue and organ types, with high expression levels in the testes, ovary, brain, lung and heart. Most mesenchyme, smooth muscle and some epithelial cells (breast, prostate, lung, ovary) express significant AKAP12 levels. Lower levels of AKAP12 are found in endothelial cells, although express in these cells is usually associated with wounding and/or inflammation. |
| Localisation | Most cell types display a cortical cytoskeletal staining pattern for AKAP12, with enrichment at the plasma membrane (presumably, the myristylated isoforms) and in the perinucleus. However, some staining has been observed in cell nuclei, probably directed by 4 SV40 Tag-like nuclear localization signals (NLS) found in the N-terminal third of the protein. |
| Function | 1) Facilitates the sensitization/resensitization reaction of beta-adrenergic receptors. 2) Scaffolds protein kinase (PK) A and PKC. 3) Autoantigen in some cases of myasthenia gravis. 4) Anti-angiogenic factor. The rodent orthologue has been shown to inhibit brain angiogenesis and induce the blood-brain barrier, and to inhibit VEGF-mediated metastasis. 5) Potential tumor suppressor. The rodent orthologue has been shown to suppress Src- and Ras-induced oncogenic proliferation in vitro and metastatic potential in vivo. |
| Homology | Southern blotting analysis as well as analysis of sequenced genomes indicates that vertebrates encode single AKAP12 orthologues, with no gene family members. Thus, the protein diversity of this gene stems from promoter choice, alternative splicing, proteolytic maturation and post-translational modification. AKAP12 has limited sequence homology based on short domains. For example, the C-terminal AKAP domain is homologous to the analogous domain in AKP79. Also, AKAP12 shares some so-called MARCKS protein-like effector domains- positively charged stretches of amino acids involved in plasma membrane targeting. |
| Molecular cloning and preliminary characterization of a novel cytoplasmic antigen recognized by myasthenia gravis sera. |
| Gordon T, Grove B, Loftus JC, O'Toole T, McMillan R, Lindstrom J, Ginsberg MH |
| The Journal of clinical investigation. 1992 ; 90 (3) : 992-999. |
| PMID 1522245 |
| |
| Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. |
| Nauert JB, Klauck TM, Langeberg LK, Scott JD |
| Current biology : CB. 1997 ; 7 (1) : 52-62. |
| PMID 9000000 |
| |
| Dynamic complexes of beta2-adrenergic receptors with protein kinases and phosphatases and the role of gravin. |
| Shih M, Lin F, Scott JD, Wang HY, Malbon CC |
| The Journal of biological chemistry. 1999 ; 274 (3) : 1588-1595. |
| PMID 9880537 |
| |
| The scaffold protein gravin (cAMP-dependent protein kinase-anchoring protein 250) binds the beta 2-adrenergic receptor via the receptor cytoplasmic Arg-329 to Leu-413 domain and provides a mobile scaffold during desensitization. |
| Fan G, Shumay E, Wang H, Malbon CC |
| The Journal of biological chemistry. 2001 ; 276 (26) : 24005-24014. |
| PMID 11309381 |
| |
| The role of SSeCKS/gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development . |
| Gelman IH |
| Frontiers in bioscience : a journal and virtual library. 2002 ; 7 : d1782-d1797. |
| PMID 12133808 |
| |
| Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. |
| Boultwood J, Pellagatti A, Watkins F, Campbell LJ, Esoof N, Cross NC, Eagleton H, Littlewood TJ, Fidler C, Wainscoat JS |
| British journal of haematology. 2004 ; 126 (4) : 508-511. |
| PMID 15287943 |
| |
| AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. |
| Choi MC, Jong HS, Kim TY, Song SH, Lee DS, Lee JW, Kim TY, Kim NK, Bang YJ |
| Oncogene. 2004 ; 23 (42) : 7095-7103. |
| PMID 15258566 |
| |
| Multiple promoters direct expression of three AKAP12 isoforms with distinct subcellular and tissue distribution profiles. |
| Streb JW, Kitchen CM, Gelman IH, Miano JM |
| The Journal of biological chemistry. 2004 ; 279 (53) : 56014-56023. |
| PMID 15496411 |
| |
| SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition. |
| Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH |
| Cancer research. 2006 ; 66 (11) : 5599-5607. |
| PMID 16740695 |
| |